Recent Advances in Systemic Therapy of Lung Cancer

Slides:



Advertisements
Similar presentations
Cedars Sinai Medical Center
Advertisements

James R. Rigas Comprehensive Thoracic Oncology Program
Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.
Squamous-cell carcinoma - new biomarkers Rafal Dziadziuszko Medical University of Gdańsk, Poland.
Strategies to overcome resistance in NSCLC with driver mutations
William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.
Contemporary Treatment of Metastatic Non-Small Cell Lung Cancer
Staging. Treatment by Stage For early stage lung cancers, surgery or radiation alone For larger tumors (>4 cm) and N+, chemotherapy should be added.
Randomized Phase II Trial of Erlotinib (E) Alone or in Combination with Carboplatin/Paclitaxel (CP) in Never or Light Former Smokers with Advanced Lung.
Randomized Phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung.
21th WCC, Shenzhen, China, Aug 19, 2010 Guo-Liang Jiang, MD, FACR Min Fan, MD, Jiayan Chen, MD Fudan University Shanghai Cancer Center Combination of radiation.
Non-Small Cell Lung Cancer Genetic Predictors Sacha Rothschild, MD PhD Medical Oncology.
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells Colin Reisterer and Nick Swenson S. Maheswaran et al. The New England Journal of Medicine.
©American Society of Clinical Oncology All rights reserved - American Society of Clinical Oncology Provisional.
EGFR Pathway EGFR, also termed HER1 EGFR, also termed HER1 –Regulates cell division, repair, survival 1 –Likely involved in tumor metastasis 1 –Contains.
First-Line TKI Use in EGFR Mutation-Positive NSCLC
New Developments in Cancer Treatment Dulcinea Quintana, MD.
Oncology Update Louis Lao. Objective How to cure cancer in the Asian population (20min)
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.
Lung cancer perspectives. Targeted therapy : one for all or a few for one ? Miklos Pless, Winterthur
 Angiogenesis Signaling Cascades EGFR PI3K MAPK Nucleus Gene Activation Cell Cycle Progression M G1G1 S G2G2 Fos P P MAPK = mitogen-activated protein.
Fernando Cotait Maluf Diretor do Departamento de Oncologia Clínica Centro de Oncologia-Hospital São José Fernando Cotait Maluf Diretor.
Medical Oncology Department University Hospital Perugia, Italy
© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey Lung Cancer and Gefitinib  Lung cancer statistics in the.
Mechanisms of resistance to EGFR TKIs and related treatment strategies
Professor Martin Schuler MD West German Cancer Center Essen, Germany
Treatment of advanced NSCLC:
A novel 3D human tissue culture model
Overall survival in NSCLC
The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.
Sumitra Thongprasert, MD
Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
First line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer – a Cochrane Collaboration.
May 29 - June 2, 2015 TIGER-X: Rociletinib Activity in EGFR T790M Mutant NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* *CCO.
Lung cancer Gene Kukuy, MD Cardiothoracic Surgery.
Authors: Syed H. Jafri ¹, Angel I. Blanco¹, Bonnie A. Labdi², Shan Guo¹. UT Houston department of medicine, Division of Oncology Department of Pharmacy.
UPDATE ON LUNG CANCER TARGETED THERAPY Ming S. Tsao, MD, FRCPC M. Qasim Choksi Chair in Lung Cancer Translational Research University Health Network, Princess.
CtDNA NGS testing identified a high-level MET amplification (copy number of 53.6 in circulation) (Figure 1A). The test was repeated on a second tube of.
Anna Buder Institute of Cancer Research Department of Medicine I Medical University of Vienna Liquid Biopsies Analysis of circulating cell-free tumor-DNA.
Samsung Genome Institute Samsung Medical Center
Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust
Rosell R et al. Proc ASCO 2011;Abstract 7503.
CCO Independent Conference Coverage
Unità Clinica di Diagnostica Istopatologica e Molecolare
Acquired EGFR TKI resistance: What are the current therapeutic strategies? Gregory J. Riely.
The New Taxonomy of Metastatic NSCLC and Physician Treatment Based on Pathologic and Molecular Characteristics The New Taxonomy of Metastatic Non-Small.
Updates in Lung Cancer: Insights From Vienna
Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.
Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.
Figure 4 Example of a patients with CUP
EVALUATE EFFECTIVENESS OF GEFIITINIB IN FIRST LINE TREATIMENT AVANCED NSCLC PATIENTS WITH EGFR MUTATION BS TRẦN THỊ CHUNG, Ths. NGUYỄN THỊ OANH Oncology.
Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer  Howard West, MD, Rogerio Lilenbaum, MD, David Harpole,
Beyond Erlotinib: Better EGFR Inhibitors?
RESEARCH IN MOLECULAR THERAPI
First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain.
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations  Benjamin Haaland, PhD, Pui San Tan,
Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer  Jasmine.
Daniel Haber MD PhD Massachusetts General Hospital Cancer Center
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.
Third-Generation EGFR TKIs
The Nurse View: Spotlight on EGFR-Mutated NSCLC
Esteller, New England Journal of Medicine, 2008
What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?
Combined inhibition of coamplified RTKs is required for response.
Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure  Joel P. Womack,
Updates in Best Practices in Non-Small Cell Lung Cancer
Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.
Presentation transcript:

Recent Advances in Systemic Therapy of Lung Cancer Lung cancer has been in the news in the past year. Patients reading the news and seeing the ads. Drugs that are finally moving the needle. Amin Kay MD FRCPC Windsor Regional Cancer Center

Disclosure CME Support from Boehringer Ingelheim AstraZeneca Amgen

Canadian Cancer Statistics 2014

Squamous Cell Carcinoma Small Cell Lung Cancer Adenocarcinoma Non-Small Cell Squamous Cell Carcinoma Large Cell Carcinoma STAGE 4

Systemic Therapies in Lung Cancer Chemotherapy Targeted Therapies

For decades people had this idea For decades people had this idea. But was unclear which immune pathway to target successfully. The links are what the immune cells using to recognize the cancer cell and then kill it.

PD1 – PDL1 Pathway One of these links between the T-cells and Tumor cells is a brake that prevents this attack. It is a naturally-built regulatory step, that tumor cells take advantage of by over-expressing PDL1.

Nivolumab Anti-PD1 Antibody Improves survival Borghaei NEJM 2015 Opdivo Improves survival by 3 months But that’s not what we are most excited about Borghaei NEJM 2015

Nivolumab Those who respond have a lasting reponse. Borgahei NEJM 2015

Side effects of PD1 / PDL1 Drugs Overall well-tolerated Autoimmune inflammation of any organ Managed with steroids and holding the drug

Targeted Therapies Subset of patients

EGFR Pathway Key pathway of tumorogenesis. EGFR mutation turns it on constitutively. EGFR TKIs bind to intracellular domain of EGFR. Ou. Crit Rev Oncol Hematol 2012;83:407-21

Prevalence of Mutations in Lung Adenocarcinoma Other: MET amplifications 2%; HER2 1%; MEK1 0.4%; NRAS 0.2% Kris et al. J Clin Oncology 2011;29:CRA7506

Driver Mutation most likely in: UP TO Non-Smoker Female Asian Squamous: Only 1%, so don’t bother checking.

EGFR mutations in NSCLC Sequist et al. Presented at the 2012 Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL; Sept 6-8 Pao et al. PNAS 2004;101:13306-11

EGFR TKI’s GEFITINIB ERLOTINIB AFATINIB Once daily pills Can anyone name a first line EGFR inhibitor used in lung cancer? GEFITINIB ERLOTINIB AFATINIB Once daily pills Response ~ 1 year Survival: ~2 years vs 1 year

EGFR mutation testing: ASCO Guideline “…patients with NSCLC who are being considered for first-line therapy with an EGFR TKI… should have their tumor tested for EGFR mutations to determine whether an EGFR TKI or chemotherapy is the appropriate first-line therapy.” PCR Keedy et al. J Clin Oncol 2011;29:2121-7

GEFITINIB

CT scans before and after erlotinib therapy. Pan M et al. (2007) CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation Nat Clin Pract Oncol 4: 603–607 doi:10.1038/ncponc0931

ERLOTINIB

AFATINIB Irreversible More targets (EGFR subtypes) More potent More toxic OS the same in all because of cross-over

Head-to-head trial AFATINIB GEFITINIB LUX-LUNG 7

Acquired Drug Resistance Mechanisms Resistance develops within ~10 months

2nd line in T790M mutation OSIMERTINIB Janne NEJM 2015

2nd line in T790M mutation ROCILETINIB Sequist NEJM 2015

Side effects of EGFR Inhibitors Helpful for you to know about if your patient is on these drugs.

Rash EGF plays an important role in maintaining skin (EGFR expressed in basal layer of epidermis), so rash with TKI is not surprising. Possible with TKI: dry skin, pruritis (moisturize, antihistamine) Most common is acne-like rash (in appearance and location: usually face, chest). Rash 37-78% Rash may be triggered by sun exposure May get secondarily infected

Correlation between rash severity and response Management of Rash Moisturizer Minimize sun, Sunscreen Hydrocortisone 2.5% BID Clindamycin 1% BID Minocycline 100mg BID If severe: hold TKI, resume at lower dose Correlation between rash severity and response Early intervention is key to avoid serious complications. Avoid OTC acne meds, as can dry out further Almost all pts have dry skin, so should use alcohol-free emolient cream. Continue mino/doxy for 4-6 wks Hirsh. Curr Oncol 2011;18:126-38

Paronychia Inflammation/Infection of nail folds Avoid trauma, wear gloves when working with hands Emollient lotion Topical antibiotics (eg. Clinda 1%) Topical Steroid (Clobetasol) Vinegar Soak If severe: Oral Doxycycline Silver nitrate Removal of nail Plate Veinagar soak: 1:1 water and white vinegar mixture for 15min http://www.oncolink.org/experts/article.cfm?id=250 Melosky & Hirsh, Frontiers in Oncology, 2014

Hair Alterations Thinning Change in colour (Re-pigmentation) thickness Curling Fragility Eyebrows and lashes too

Mucositis Soft non-irritating foods Soft Toothbrush Normal saline or Sodium Bicarb (baking soda) rinse Miles Solution (steroid, lidocaine, nystatin) Assess for thrush and herpes

Diarrhea GI tract epithelial cells express EGFR Secretory diarrhea Incidence 27-87% in various trials

Diarrhea Assess for other causes (laxatives, antibiotics, Stool Cx / C.diff, …) Assess volume status, electrolytes Diet Modification: BRAT diet Avoid milk products, fatty/spicy foods Keep hydrated Loperamide Avoid milk products (lactase activity decreases with epithelial damage) BRAT: (bananas, rice, applesauce, toast) Loperamide: 4 mg (2 tablets) immediately after symptoms begin and then 2 mg (1 tablet) after each loose stool to a maximum of 20 mg daily until 12 hours have passed with no episodes of diarrhea Restarting at lower doses: Lower the afatinib dose by 10 mg at a time to a minimum dose of 20 mg. Lower the erlotinib dose by 50 mg at a time to a minimum dose of 50 mg (no sufficient data on efficacy are available in the literature). Resume gefitinib only at the original dose (the dose of gefitinib cannot be lowered and no data on its efficacy with a modified schedule are available)

Severe Diarrhea (Grade 3,4) Admit to Hospital IV Hydration, Electrolyte repletion Continue Imodium Consider Octreotide Rule out other causes (eg. C.diff, Imaging, Scope) Hold drug Restart at lower dose when improves to grade 1. Watch out for flare when holding TKI.

Prevalence of Mutations in Lung Adenocarcinoma Other: MET amplifications 2%; HER2 1%; MEK1 0.4%; NRAS 0.2% Kris et al. J Clin Oncology 2011;29:CRA7506

EML4-ALK Rearrangement FISH

CRIZOTINIB

Pneumonitis Bradycardia Visual effects: Visual persistence (trailer), halos Self-limited, no intervention required Well tolerated (Grade 3,4 toxicity is very rare) Pneumonitis Bradycardia

2nd line ALK inhibitors CERITINIB ALECTINIB More potent, better CNS response.